EntreMed's (ENMD) ENMD-2076 Showed Anti-cancer Activity in Platinum-resistant Ovarian Cancer
Publicat de acum 8 vizionari0 comentarii
Ovarian cancer is still the fourth cause of death by cancer among women and is the most fatal among gynaecological tumours–I’m Christina Collins with CRWE Newswire — Today’s company highlight is EntreMed Incorporated trading with the symbol ENMD–EntreMed Incorporated is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer–EntreMed recently reported clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients–The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer–According to the company, ENMD-2076 has demonstrated impressive anti-cancer activity in platinum-resistant ovarian cancer- which is notoriously difficult to treat, and these patients have few options–EntreMed’s ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers, leukemia, and multiple myeloma. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound’s applicability in other forms of cancer–For more information about EntreMed Incorporated, symbol ENMD, visit www.entremed.com. I’m Christina Collins with CRWE Newswire
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.